A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669.

Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

Annals of Oncology ◽

10.1093/annonc/mdv514.01 ◽

2015 ◽

Vol 26 ◽

pp. viii5 ◽

Cited By ~ 4

Author(s):

A. Klochikhin ◽

R. Greil ◽

E. Cohen ◽

J. Vermorken ◽

K. Harrington ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

480TiP Phase 3, randomised, open-label study of durvalumab (MEDI4736) in combination with tremelimumab versus platinum-based chemotherapy in first-line treatment of patients with advanced or metastatic NSCLC: NEPTUNE

Annals of Oncology ◽

10.1093/annonc/mdv532.64 ◽

2015 ◽

Vol 26 ◽

pp. ix125

Author(s):

T. Mok ◽

P. Schmid ◽

O. Arén ◽

O. Arrieta ◽

M. Gottfried ◽

...

Keyword(s):

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study ◽

Metastatic Nsclc ◽

Platinum Based Chemotherapy ◽

342TiP Phase 3 trial of pembrolizumab as a first-line treatment in subjects with recurrent/metastatic head and neck squamous cell carcinoma: KEYNOTE-048

Annals of Oncology ◽

10.1093/annonc/mdv527.29 ◽

2015 ◽

Vol 26 ◽

pp. ix93 ◽

Cited By ~ 1

Author(s):

C.J. Yen ◽

A. Klochikhin ◽

E. Cohen ◽

J. Vermorken ◽

K. Harrington ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Phase 3 ◽

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30755-5 ◽

2021 ◽

Vol 22 (4) ◽

pp. 463-475

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jérôme Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma

Case Medical Research ◽

10.31525/cmr-14e3317 ◽

2019 ◽

Author(s):

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Cetuximab, Docetaxel and Cisplatin as First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results of the GORTEC 2014-01 TPExtreme Randomized Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3700967 ◽

2020 ◽

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jerome Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Randomized Trial ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

First Line ◽

Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)

Annals of Oncology ◽

10.1093/annonc/mdw376.19 ◽

2016 ◽

Vol 27 ◽

pp. vi334 ◽

Cited By ~ 2

Author(s):

J. Guigay ◽

E. Chamorey ◽

P. Céruse ◽

F. Mornex ◽

M. Degardin ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Observational Study ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Intensity ◽

Line Treatment ◽

First Line ◽

Metastatic Squamous Cell Carcinoma ◽

Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR

Journal for ImmunoTherapy of Cancer ◽

10.1186/2051-1426-3-s2-p152 ◽

2015 ◽

Vol 3 (S2) ◽

Cited By ~ 6

Author(s):

Jill Gilbert ◽

Christophe Le Tourneau ◽

Hisham Mehanna ◽

Jerome Fayette ◽

Trishna Goswami ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Open Label ◽

Open Label Study ◽

Label Study

A phase I, open-label study (EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Radiotherapy and Oncology ◽

10.1016/s0167-8140(07)80091-0 ◽

2007 ◽

Vol 82 ◽

pp. S30 ◽

Cited By ~ 1

Author(s):

I. El-Hariry ◽

K. Harrington ◽

J. Bourhis ◽

C. Holford

Keyword(s):

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Open Label ◽

Open Label Study ◽

Label Study

972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1087 ◽

2020 ◽

Vol 31 ◽

pp. S683

Author(s):

K.J. Harrington ◽

W.N. William ◽

A. Khilnani ◽

A.P. Algazi

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Recurrent Head ◽